Global Markets Direct’s pharmaceuticals report, “Vecta Ltd. - Product Pipeline Review - 2013” provides data on the Vecta Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vecta Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Vecta Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Vecta Ltd. - Brief Vecta Ltd. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Vecta Ltd. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Vecta Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Vecta Ltd.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Vecta Ltd.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Vecta Ltd. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Vecta Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Vecta Ltd.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Vecta Ltd. and identify potential opportunities in those areas.
Table Of Contents
Vecta Ltd. - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Vecta Ltd. Snapshot 4 Vecta Ltd. Overview 4 Key Information 4 Key Facts 4 Vecta Ltd. - Research and Development Overview 5 Key Therapeutic Areas 5 Vecta Ltd. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Combination Treatment Modalities 9 Vecta Ltd. - Pipeline Products Glance 10 Vecta Ltd. Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 Vecta Ltd. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Vecta Ltd. - Drug Profiles 14 (Vecam + amoxicillin) 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 AVEC 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 PIVEC 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 Vecam 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 Vecta Ltd. - Pipeline Analysis 18 Vecta Ltd. - Pipeline Products by Therapeutic Class 18 Vecta Ltd. - Pipeline Products By Target 19 Vecta Ltd. - Pipeline Products by Route of Administration 20 Vecta Ltd. - Pipeline Products By Mechanism of Action 21 Vecta Ltd. - Locations And Subsidiaries 22 Head Office 22 Appendix 23 Methodology 23 Coverage 23 Secondary Research 23 Primary Research 23 Expert Panel Validation 23 Contact Us 24 Disclaimer 24
List of Tables
Vecta Ltd., Key Information 4 Vecta Ltd., Key Facts 4 Vecta Ltd. - Pipeline by Indication, 2013 6 Vecta Ltd. - Pipeline by Stage of Development, 2013 7 Vecta Ltd. - Monotherapy Products in Pipeline, 2013 8 Vecta Ltd. - Combination Treatment Modalities in Pipeline, 2013 9 Vecta Ltd. - Phase II, 2013 10 Vecta Ltd. - Phase I, 2013 11 Vecta Ltd. - Preclinical, 2013 12 Vecta Ltd. - Discovery, 2013 13 Vecta Ltd. - Pipeline By Therapeutic Class, 2013 18 Vecta Ltd. - Pipeline By Target, 2013 19 Vecta Ltd. - Pipeline By Route of Administration, 2013 20 Vecta Ltd. - Pipeline Products By Mechanism of Action, 2013 21
List of Figures
Vecta Ltd. - Pipeline by Indication, 2013 6 Vecta Ltd. - Pipeline by Stage of Development, 2013 7 Vecta Ltd. - Monotherapy Products in Pipeline, 2013 8 Vecta Ltd. - Combination Treatment Modalities in Pipeline, 2013 9 Vecta Ltd. - Pipeline By Therapeutic Class, 2013 18 Vecta Ltd. - Pipeline Products By Mechanism of Action, 2013 21